Carterra Ultra™: Revolutionizing Drug Discovery
Carterra Inc. has proudly introduced Carterra Ultra™, a cutting-edge advancement in high-throughput biology technologies. This innovative platform enhances the capabilities of its existing LSA® and LSA XT systems, specifically tailored for the precise and sensitive characterization of small molecules.
Enhanced High-Throughput Features
The Ultra platform signifies a major leap forward in drug discovery techniques, allowing researchers to swiftly analyze small molecules while maintaining the high throughput characteristic of Carterra's previous systems. Its sensitive design enables the characterization of molecules as small as 100 Daltons, making it an essential resource for both pharmaceutical and biotechnological research.
Notable Features of Carterra Ultra
With upgraded optics and sophisticated microfluidics, the Ultra platform excels in delivering high-sensitivity measurements. Its array-based format is specifically optimized for Fragment-Based Lead Discovery (FBLD), featuring rigorous thermal control that allows for interactions to be assessed at lower temperatures, as low as 10°C. This capability represents a significant enhancement over existing systems.
Speeding Up Drug Discovery
Dr. Phillip Schwartz, a leading expert in drug discovery, has expressed his excitement about the Ultra platform. He highlights its capacity to conduct extensive testing of molecular interactions simultaneously. He believes that this groundbreaking technology will significantly accelerate drug discovery processes, allowing researchers to more efficiently identify relevant protein targets and advance the search for new medicines.
Applications in AI and Deep Learning
The Ultra platform is also noteworthy for its applications in artificial intelligence and machine learning (AI/ML) initiatives. As researchers increasingly utilize AI to enhance drug discovery, the Ultra facilitates comprehensive evaluations of binding interactions and assists in exploring new indications for existing disease targets.
Insights from Leadership
Josh Eckman, CEO of Carterra, emphasizes the critical need for the rapid development of new life-saving medicines. He points out that the Ultra platform is designed to speed up the discovery of new small-molecule drugs through its innovative multiplex SPR format, which requires minimal samples while producing high-resolution data for informed decision-making.
First Public Appearance of Carterra Ultra
The Ultra platform is scheduled to make its debut at significant industry events. It will first be showcased at the Fragment-Based Lead Discovery conference and subsequently at ELRIG's Drug Discovery event. These venues will provide an opportunity to demonstrate its capabilities to potential users in both academia and industry.
Contact Information for Media Inquiries
Carterra welcomes inquiries from interested parties. For media inquiries, please reach out to Cheri Salazar at (408) 594-9400. For more information about their innovations, you can contact Carterra directly.
About Carterra, Inc.
Carterra, Inc. is well-known for its pioneering technologies that significantly enhance the discovery of therapeutic candidates. Their platforms, including LSA, LSA XT, and Ultra, utilize patented microfluidics combined with real-time High-Throughput Surface Plasmon Resonance (HT-SPR), leading the way in innovative drug development methodologies. By improving throughput and minimizing sample volumes, Carterra empowers researchers to make significant strides in biotherapeutics and small molecule analysis.
Frequently Asked Questions
What is Carterra Ultra™?
Carterra Ultra™ is an advanced biosensor platform designed for high-throughput characterization of small molecules and fragments, offering enhanced sensitivity and throughput.
How does Carterra Ultra™ improve drug discovery?
It accelerates workflows by providing rapid and precise molecular interaction data, thus enabling faster decision-making in drug development.
What are the key features of the Ultra platform?
Ultra features advanced optics, improved microfluidics, and the capability to measure interactions at lower temperatures, specifically aimed at Fragment-Based Lead Discovery.
Where will Carterra Ultra™ be showcased?
The platform will publicly debut at the Fragment-Based Lead Discovery conference and later at ELRIG's Drug Discovery event in London.
Who can benefit from the Carterra Ultra™ platform?
Researchers and pharmaceutical companies focusing on drug discovery and development will benefit from the Ultra platform's high-throughput and low-sample capabilities.
